Table 1.
Host | n | Recipient Igh | PerC§ Igh | % B-2* ± SD | % B-1* ± SD | Serum IgMa, μg/ml | Serum IgMb, μg/ml |
---|---|---|---|---|---|---|---|
μ−/− | 8 | Ighb | Igha | 0.3 ± 0.3 | 0.03 ± 0.02 | < 0.015 | < 0.015 |
C57-Ab† | 7 | Ighb | Igha | 11 ± 2.6 | 18 ± 2.4 | 250 ± 48 | 330 ± 59 |
RAG−/−‡ | 5 | Ighb | Igha | 3.6 ± 2.4 | 19 ± 5.4 | 230 ± 89 | 540 ± 440 |
C57/Igha | 6 | Igha | None | 22 ± 2.4 | 26 ± 3.7 | 210 ± 130 | < 0.015 |
C57BL/6 | 7 | Ighb | None | 13 ± 5.2 | 22 ± 5.5 | < 0.015 | 590 ± 380 |
*Shown is the frequency (± SD) of cells among total live recipient PerC cells.
†Mice were treated from birth for 6 weeks with a total of 2 mg per mouse anti-IgMb.
‡Mice received i.v. 3 × 106 bone marrow from C57BL/6 2–3 months before analysis.
§Mice received 5 × 106 PerC cells from C57/Igha 2–3 months before analysis.